Fiera Capital Corp Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Fiera Capital Corp lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,127,719 shares of the company's stock after selling 100,626 shares during the quarter. Johnson & Johnson comprises approximately 1.4% of Fiera Capital Corp's investment portfolio, making the stock its 20th biggest holding. Fiera Capital Corp owned 0.13% of Johnson & Johnson worth $452,331,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of JNJ. Powers Advisory Group LLC lifted its position in Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after purchasing an additional 61 shares during the period. Knuff & Co LLC lifted its holdings in shares of Johnson & Johnson by 0.7% in the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after acquiring an additional 64 shares during the last quarter. Vertex Planning Partners LLC lifted its holdings in shares of Johnson & Johnson by 1.3% in the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock worth $844,000 after acquiring an additional 65 shares during the last quarter. Freedom Day Solutions LLC lifted its holdings in shares of Johnson & Johnson by 1.1% in the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company's stock worth $1,016,000 after acquiring an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.6% in the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company's stock worth $1,699,000 after acquiring an additional 67 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 1.9 %

Shares of JNJ traded up $2.94 during trading hours on Wednesday, reaching $157.93. The stock had a trading volume of 7,830,622 shares, compared to its average volume of 9,018,342. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a 50-day simple moving average of $148.12 and a 200 day simple moving average of $155.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $380.23 billion, a price-to-earnings ratio of 23.75, a P/E/G ratio of 2.50 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period last year, the business earned $2.29 EPS. Johnson & Johnson's quarterly revenue was up 5.3% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.14%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective for the company. Guggenheim upped their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Barclays upped their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Finally, Citigroup decreased their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $170.67.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.